
Opinion|Videos|April 28, 2025
Clinical Benefits of BPH Treatments
Author(s)Christopher E. Kelly, MD
Panelist discusses how clinical data from multiple studies demonstrate that aqua ablation therapy offers efficacy comparable with that of transurethral resection of the prostate (TURP) while providing superior safety, functionality, and durability benefits.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Aqua Ablation Therapy Benefits
Efficacy:
- Aqua ablation demonstrates noninferior, equal, or superior results compared with TURP (gold standard).
- Measured by International Prostate Symptom Score and Qmax (flow rate).
- 5-year data confirm strong symptom improvement comparable with TURP.
Safety:
- Urinary incontinence:0.1% (aqua ablation) vs up to 7%+ (TURP)
- Blood transfusion rate:0.1% (aqua ablation), lower than TURP
- Ejaculation preservation:89%-90% (aqua ablation) vs ~75% (TURP)
- Erectile dysfunction rate:0% for aqua ablation
Durability:
- Retreatment rate (5 years):
- TURP: ~12%
- Aqua ablation: ~6% (half of TURP’s rate)
Aqua ablation provides a safer, more durable alternative to TURP with comparable or superior efficacy.
Advertisement
Related to this article

These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.

Patient goals, disease features, and response to prior therapy guide treatment choices across high-risk NMIBC, according to Suzanne B. Merrill, MD, FACS.

Suzanne B. Merrill, MD, discusses emerging perioperative approaches in MIBC and the potential for more personalized treatment selection based on disease characteristics.

BCG monotherapy and a high-quality TURBT remain the foundation for BCG-naive high-risk NMIBC, according to Vignesh T. Packiam, MD.

Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.

Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.

Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Advertisement
Advertisement
Trending on Urology Times
1
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
2
Modern BCG outperforms historic benchmarks in high-risk NMIBC
3
Q&A: Gary Kirsh, MD, on health policy for independent urology
4
Suzanne B. Merrill, MD, on the evolving perioperative landscape in MIBC
5

